Implementation of lung cancer screening in Europe: challenges and potential solutions: summary of a multidisciplinary roundtable discussion.
Lung cancer screening
lung cancer mortality
nodule management
patient recruitment
secondary care pathways
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
2019
2019
Historique:
received:
14
08
2019
revised:
19
09
2019
accepted:
21
09
2019
entrez:
2
11
2019
pubmed:
2
11
2019
medline:
2
11
2019
Statut:
epublish
Résumé
Recent randomised trials on screening with low-dose CT have shown important reductions in lung cancer (LC) mortality and have triggered international efforts to implement LC screening. Detection rates of stage I LC with volume CT approaching 70% have been demonstrated. In April 2019 'ESMO Open - Cancer Horizons' convened a roundtable discussion on the challenges and potential solutions regarding the implementation of LC screening in Europe. The expert panel reviewed the current evidence for LC screening with low-dose CT and discussed the next steps, which are covered in this article. The panel concluded that national health policy groups in Europe should start to implement CT screening as adequate evidence is available. It was recognised that there are opportunities to improve the screening process through 'Implementation Research Programmes'.
Identifiants
pubmed: 31673428
doi: 10.1136/esmoopen-2019-000577
pii: S2059-7029(20)30127-7
pmc: PMC6802961
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e000577Subventions
Organisme : Department of Health
ID : 09/61/01
Pays : United Kingdom
Informations de copyright
© Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.
Références
BMC Cancer. 2018 Feb 13;18(1):181
pubmed: 29439651
J Natl Cancer Inst. 2011 Jul 6;103(13):1058-68
pubmed: 21606442
Ann Transl Med. 2016 Apr;4(8):155
pubmed: 27195273
Thorax. 2015 Aug;70 Suppl 2:ii1-ii54
pubmed: 26082159
Thorax. 2017 Jan;72(1):48-56
pubmed: 27364640
Thorax. 2017 Jan;72(1):6-7
pubmed: 27974632
N Engl J Med. 2009 Dec 3;361(23):2221-9
pubmed: 19955524
Thorax. 2018 Aug;73(8):779-781
pubmed: 29056601
PLoS One. 2013 Aug 07;8(8):e71379
pubmed: 23940744
J Thorac Oncol. 2019 Mar;14(3):343-357
pubmed: 30529598
Br J Cancer. 2008 Jan 29;98(2):270-6
pubmed: 18087271
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Am Health Drug Benefits. 2014 Aug;7(5):272-82
pubmed: 25237423
Thorax. 2019 Mar;74(3):247-253
pubmed: 30591535
Br J Radiol. 2018 Oct;91(1090):20170401
pubmed: 28830225
Health Technol Assess. 2016 May;20(40):1-146
pubmed: 27224642
Lancet Oncol. 2017 Dec;18(12):e754-e766
pubmed: 29208441
Eur J Cancer. 2019 Sep;118:142-148
pubmed: 31336289
Transl Lung Cancer Res. 2018 Jun;7(3):281-287
pubmed: 30050766
Ann Intern Med. 2014 Mar 4;160(5):311-20
pubmed: 24379002
J Natl Cancer Inst. 2019 Sep 1;111(9):996-999
pubmed: 30976808
Lung Cancer. 2019 Aug;134:66-71
pubmed: 31319997
Lancet Oncol. 2014 Nov;15(12):1332-41
pubmed: 25282285
Ann Oncol. 2019 Jul 1;30(7):1162-1169
pubmed: 30937431
Eur J Epidemiol. 2020 Jan;35(1):75-86
pubmed: 31016436
Cancer Res. 2017 Nov 1;77(21):5717-5720
pubmed: 28993413
Int J Cardiovasc Imaging. 2019 Jul;35(7):1319-1325
pubmed: 31093894